Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity drops Capital to 'hold', slashes target price

(Sharecast News) - Analysts at Canaccord Genuity slashed their target price on mining services firm Capital from 130.0p to 60.0p on Tuesday and dropped the stock from 'buy' to 'hold' following disappointing FY25 revenue guidance. Capital announced FY25 revenue guidance of $300.0-320.0m, weighted to H2, implying an 8-14% decrease versus. Canaccord noted the revenue decline could be attributed to lower mining revenues, while MSALABS growth has also been slower than anticipated and not enough to offset the broader decline.

Canaccord stated that when it initially formed its thesis, a key component was the company's ability to operate in a difficult jurisdiction, where the competition was more fractured and margins were higher, which led to higher capital efficiency than drilling peers.

Since then, however, the company has pivoted towards lower margin businesses, and the US, which has required a significant increase in capital investment.

The Canadian bank also noted that the company's NGM drilling contract has seen delays, which has negatively impacted group margins. Similarly, Capital has also consistently missed its revenue guidance for the MSALABS business since 2022, with the latest FY25 guidance of $50.0-60.0m significantly lower than the $80.0m previously targeted.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.